References
- Economopoulou P, De Bree R, Kotsantis I, et al. Diagnostic tumor markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the clinical setting. Front Oncol. 2019;9:827.
- Miyauchi S, Kim SS, Pang J, et al. Immune modulation of head and neck squamous cell carcinoma and the tumor microenvironment by conventional therapeutics. Clin Cancer Res. 2019;25(14):4211–4223.
- Wang X, Cao K, Guo E, et al. Identification of immune-Related LncRNA pairs for predicting prognosis and immunotherapeutic response in head and neck squamous cell carcinoma. Front Immunol. 2021;12:658631.
- Wang HC, Chan LP, Cho SF. Targeting the immune microenvironment in the treatment of head and neck squamous cell carcinoma. Front Oncol. 2019;9:1084.
- Ebnoether E, Diagnostic ML. Therapeutic applications of exosomes in cancer with a special focus on Head and Neck Squamous Cell Carcinoma (HNSCC). Int J Mol Sci. 2020;21(12):4344.
- Yang QQ, Deng YF. (2014) Long non-coding RNAs as novel biomarkers and therapeutic targets in head and neck cancers. Int J Clin Exp Pathol. 2014;7(4):1286–1292.
- Xing C, Sun SG, Yue ZQ, et al. Role of lncRNA LUCAT1 in cancer. Biomed Pharmacother. 2021;134:111158.
- Ulitsky I, Bartel DP. lincRNAs: genomics, evolution, and mechanisms. Cell. 2013;154(1):26–46.
- Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7–21.
- Zhang X, Wang W, Zhu W, et al. Mechanisms and functions of long non-coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22):5573.
- Zhao J, Liu D, Yang H, et al. Long noncoding RNAs in head and neck squamous cell carcinoma: biological functions and mechanisms. Mol Biol Rep. 2020;47(10):8075–8090.
- Zheng S, Guo Y, Dai L, et al. Long intergenic noncoding RNA01134 accelerates hepatocellular carcinoma progression by sponging microRNA-4784 and downregulating structure specific recognition protein 1. Bioengineered. 2020;11(1):1016–1026.
- Li D, Feng J, Wu T, et al. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am J Pathol. 2013;182(1):64–70.
- Zhou H, Jia X, Yang F, et al. Long noncoding RNA SATB1-AS1 contributes to the chemotherapy resistance through the microRNA-580/ 2ʹ-5ʹ-oligoadenylate synthetase 2 axis in acute myeloid leukemia. Bioengineered. 2021;12(1):6403–6417.
- Yan X, Hu Z, Feng Y, et al. Comprehensive genomic characterization of long non-coding RNAs across human cancers. Cancer Cell. 2015;28(4):529–540.
- Li W, Chen QF, Huang T, et al. Identification and validation of a prognostic lncrna signature for hepatocellular carcinoma. Front Oncol. 2020;10:780.
- Xia P, Li Q, Wu G, et al. An immune-related lncRNA signature to predict survival in glioma patients. Cell Mol Neurobiol. 2021;41(2):365–375.
- Ma B, Li Y, Ren Y. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer. Cancer Med. 2020;9(1):335–349.
- Pijuan J, Barceló C, Moreno DF, et al. In vitro cell migration, invasion, and adhesion assays: from cell imaging to data analysis. Front Cell Dev Biol. 2019;14(7):107.
- Muzaffar J, Bari S, Kirtane K, et al. Recent advances and future directions in clinical management of head and neck squamous cell carcinoma. Cancers (Basel). 2021;13(2):338.
- Li Z, Yan M, Yu Y, et al. LncRNA H19 promotes the committed differentiation of stem cells from apical papilla via miR-141/SPAG9 pathway. Cell Death Dis. 2019;10(2):130.
- Liang Y, Song X, Li Y, et al. A novel long non-coding RNA-PRLB acts as a tumor promoter through regulating miR-4766-5p/SIRT1 axis in breast cancer. Cell Death Dis. 2018;9(5):563.
- Zhuo W, Liu Y, Li S, et al. Long noncoding RNA GMAN, Up-regulated in gastric cancer tissues, is associated with metastasis in patients and promotes translation of ephrin A1 by competitively binding GMAN-AS. Gastroenterology. 2019;156(3):676–691.
- Hu Q, Ye Y, Chan LC, et al. Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. Nat Immunol. 2019;20(7):835–851.
- Chi Y, Wang D, Wang J, et al. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019;8(9):1015.
- Li W, Chen QF, Huang T, et al. Identification and validation of a prognostic lncRNA signature for hepatocellular carcinoma. Front Oncol. 2020;10:780.
- Hu Q, Tai S, Wang J. Oncogenicity of lncRNA FOXD2-AS1 and its molecular mechanisms in human cancers. Pathol Res Pract. 2019;215(5):843–848.
- Ni W, Xia Y, Bi Y, et al. FoxD2-AS1 promotes glioma progression by regulating miR-185-5P/HMGA2 axis and PI3K/AKT signaling pathway. Aging (Albany NY). 2019;11(5):1427–1439.
- Zhang M, Jiang X, Jiang S, et al. LncRNA FOXD2-AS1 regulates miR-25-3p/Sema4c axis to promote the invasion and migration of colorectal cancer cells. Cancer Manag Res. 2019;11:10633–10639.
- Jiang M, Qiu N, Xia H, et al. Long non‑coding RNA FOXD2‑AS1/miR‑150‑5p/PFN2 axis regulates breast cancer malignancy and tumorigenesis. Int J Oncol. 2019;54(3):1043–1052.
- Gao J, Dai C, Yu X, et al. Silencing of long non-coding RNA FOXD2-AS1 inhibits the progression of gallbladder cancer by mediating methylation of MLH1. Gene Ther. 2021;28(6):306–318.
- Zhao T, Zhang J, Ye C, et al. lncRNA FOXD2-AS1 promotes hemangioma progression through the miR-324-3p/PDRG1 pathway. Cancer Cell Int. 2020;20(1):189.
- Chen DZ, Wang TF, Dai WC, et al. LncRNA FOXD2-AS1 accelerates the progression of cervical cancer via downregulating CDX1. Eur Rev Med Pharmacol Sci. 2019;23(23):10234–10240.
- Xiao Y, Lucas B, Molcho E, et al. Inhibition of CDK1 activity by sumoylation. Biochem Biophys Res Commun. 2016;478(2):919–923.
- Zhang L, Kang W, Lu X, et al. LncRNA CASC11 promoted gastric cancer cell proliferation, migration and invasion in vitro by regulating cell cycle pathway. Cell Cycle (Georgetown, Tex). 2018;17(15):1886–1900.
- Qin H, Liu W. MicroRNA-99a-5p suppresses breast cancer progression and cell-cycle pathway through downregulating CDC25A. J Cell Physiol. 2019;234(4):3526–3537.
- Göttgens EL, Bussink J, Leszczynska KB, et al. Inhibition of CDK4/CDK6 enhances radiosensitivity of HPV negative head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 2019;105(3):548–558.
- Bidaud P, Chasle J, Sichel F, et al. Expression of p53 family members and CD44 in oral squamous cell carcinoma (OSCC) in relation to tumorigenesis. Histol Histopathol. 2010;25(3):331–339.
- Chen H, Guo Y, Huang J, et al. Upregulating hsa-miR-128a increased the effects of pembrolizumab on laryngeal cancer cells via the p53 pathway. Biomed Res Int. 2021;2021:2342784.